Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to $589,000.

  • Compass Therapeutics' Depreciation & Amortization (CF) fell 86.71% to $19,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $399,000, marking a year-over-year decrease of 34.59%. This contributed to the annual value of $589,000 for FY2024, which is 15.74% down from last year.
  • According to the latest figures from FY2024, Compass Therapeutics' Depreciation & Amortization (CF) is $589,000, which was down 15.74% from $699,000 recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Depreciation & Amortization (CF) ranged from a high of $2.4 million in FY2020 and a low of $566,000 during FY2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $690,000, with a median of $699,000 in 2023.
  • As far as peak fluctuations go, Compass Therapeutics' Depreciation & Amortization (CF) slumped by 76.46% in 2021, and later surged by 38.16% in 2022.
  • Compass Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $2.4 million in 2020, then plummeted by 76.46% to $566,000 in 2021, then spiked by 38.16% to $782,000 in 2022, then decreased by 10.61% to $699,000 in 2023, then dropped by 15.74% to $589,000 in 2024.